High flow nasal therapy use in patients with acute exacerbation of COPD and bronchiectasis: a feasibility study.

Claudia Crimi¹, Alberto Noto², Andrea Cortegiani³, Raffaele Campisi¹, Enrico Heffler⁴, Cesare Gregoretti³, Nunzio Crimi⁵

¹Respiratory Medicine Unit, A.O.U. “Policlinico-Vittorio Emanuele”, Via S. Sofia, 78, 95123, Catania, Italy
²Department of Anaesthesia and Intensive Care, AOU G. Martino, University of Messina, Messina
³Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), Section of Anesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy
⁴Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI Italy.
Personalized Medicine, Allergy and Asthma - Humanitas Clinical and Research Center - IRCCS, Via Alessandro Manzoni 56, 20089 Rozzano, MI Italy.
⁵Respiratory Medicine Unit, A.O.U. "Policlinico-Vittorio Emanuele", Department of Clinical and Experimental Medicine, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy

Running head: High flow nasal therapy in COPD and bronchiectasis.

*Corresponding Author
Claudia Crimi
Respiratory Medicine Unit
A.O.U. "Policlinico-Vittorio Emanuele", University of Catania
Via Santa Sofia 78
Catania, 95123, Italy
Tel: +390953781423
Fax: +390953781423
E-mail:dott.claudiacrimi@gmail.com

Keywords: high flow nasal cannula, acute respiratory failure, COPD, bronchiectasis, humidification, sputum, mucus plug
ABSTRACT

The efficacy and feasibility of high flow nasal therapy (HFNT) use in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and bronchiectasis is unknown. We performed a single-center, single-arm prospective observational study in patients with AECOPD, documented bronchiectasis, pH ≥ 7.35, respiratory rate (RR) > 26 breaths/minute despite receiving maximal medical treatment and oxygen via face mask up to 10 L/m. Patients received HFNT (Airvo 2, Fisher & Paykel) at a gas flow of 50 L/min and FIO2 adjusted to maintain SpO2 ≥92%. Dyspnea, rated by Borg scale, RR, arterial blood gases and mucus production (ranging from 1 to 3) were collected before and 1 h after starting HFNT and then every 24 h for 3 days. Tolerance was measured using a visual analogic scale (VAS).

Fifteen patients were enrolled. After 24 hours, patients showed a significant improvement in dyspnea score [Borg scale from 6[1]4±1.4 to 4[1]3±1.3 (p<.001)]; RR decreased from 29[1]7±2.7 breaths/min to 23[2]9±2.9 breaths/min (p<.001); pCO2 significantly decreased after 24 h [58.4±13 vs. 51.7±8.2 (p=.003)] while quantity of mucus production increased [(1.1±0.6 vs. 2.4±0.7, p<.001)]. No patient received invasive or noninvasive mechanical ventilation. Overall VAS score for HFNT tolerance was 6[1]5.

HFNT was effective in improving dyspnea score, decreasing RR, improving gas exchange, and increasing mucus production in patients with AECOPD and coexisting bronchiectasis. Moreover, no safety concerns on its use were detected. Nevertheless, due to the single-arm design, the effect of HFNT could not be isolated from standard pharmacological treatment due to the study design.
INTRODUCTION

Bronchiectasis is a frequent comorbidity in patients with chronic airway diseases [1], determining a more severe phenotype in both asthma [2] and chronic obstructive pulmonary disease (COPD) [3]. Moreover, COPD-related bronchiectasis has an independent impact on disease course and outcomes, [4] leading to a worse prognosis [5], increased severity of exacerbation [6] and mortality rate [7]. Indeed, patients with bronchiectasis during acute exacerbations very often have an increased secretion viscosity, worsening sputum retention and consequently an increase in respiratory impedance and work of breathing [8]. Therefore, COPD severity, during acute exacerbation of COPD (AECOPD) may be influenced by coexisting bronchiectasis [9].

High-flow nasal therapy (HFNT) has become an increasingly used modality for the management of patients with type 1 and type 2 acute respiratory failure in different clinical settings [10, 11, 12]. HFNT delivers high flow gas (up to 60 L/min), warmed to body temperature, saturated for reaching optimal humidification (37 degrees, 44 mg H2O/L) and eventually oxygen-enriched to achieve an inspiratory oxygen fraction up to 100% [13, 14]. From a physiological point of view, the delivery of warmed humidified gas by HFNT preserves mucociliary transport and promotes mobilization of secretions [15], preventing mucus plugging that may obstruct the airway and decrease ventilation.

Recently, some studies showed the beneficial effects of heated humidification therapy on mucociliary clearance and ventilation in patients with bronchiectasis [16, 17] and COPD [18, 19, 20], both muco-obstructive diseases characterized by airway inflammation, mucus hypersecretion and impaired mucociliary transport [21]. Nevertheless, few data exist about the use of HFNT for the treatment of bronchiectasis and bronchiectasis-COPD exacerbations.

We hypothesized that HFNT may be effective and well tolerated in patients with AECOPD and concomitant bronchiectasis in terms of gas exchange, respiratory rate, and mucus expectoration; therefore we performed a prospective observational study to evaluate the feasibility of a randomized controlled trial (RCT).
METHODS

Patients and setting

We performed a prospective single-arm, observational study from September 2018 to October 2019 in patients admitted to the Respiratory Medicine Unit of AOU Policlinico Vittorio Emanuele di Catania for AECOPD and concomitant bronchiectasis.

All the patients considered for this observational feasibility study were treated according to routine care and not assigned with a specific treatment by investigators’ ad hoc for the study.

The inclusion criteria were as follows: acute respiratory failure (ARF) define as PaO$_2$/FIO$_2$<300 mmHg and arterial blood pH $\geq$ 7.35); respiratory rate (RR) $\geq$ 26 breaths/min despite receiving maximal medical treatment [22] and after 1 hour of oxygen via Venturi mask (O$_2$ max 10 L/min); COPD GOLD Class $\geq$ 2 (based on GOLD classification of severity of airflow limitation) [22]; MRC (Medical Research Council) dyspnea score $\geq$ 2; history of documented bronchiectasis [confirmed by a recent (< 1 year) chest computed tomography].

The presence of bronchiectasis was detected by an independent radiologist who performed the patient’s chest CT scan and then confirmed by a respiratory physician (RC) who was unaware of the patient’s clinical condition. Bronchiectasis was defined as present if the broncho-arterial ratio was equal to or greater than 1 [23].

We excluded patients with: life-threatening hypoxemia (PaO$_2$/FIO$_2$ < 100 mm Hg) requiring noninvasive ventilation (NIV) or intubation, acidosis (pH< 7.35) requiring NIV or intubation, tracheostomy, receiving NIV in the emergency department, domiciliary long-term NIV, malignant co-morbidities, hemodynamic instability (systolic arterial pressure < 90 mm Hg or mean arterial pressure < 60 mm Hg, or use of vasoactive agents), severe heart failure (New York Heart Association stage IV), unstable angina/myocardial infarction or severe arrhythmias [24], pulmonary embolism, pulmonary infiltrates of new origin suggesting pneumonia, abnormalities of the thorax or...
lung diseases other than COPD/bronchiectasis, refusal of consent. All enrolled patients signed written informed consent.

The study was approved by the Ethics Committee “Catania 1” of AOU Policlinico-Vittorio Emanuele di Catania (N°176/2018/PO).

**Study design**

The study design is shown in figure 1. In brief, patients with AECOPD and bronchiectasis who remained tachypneic despite maximal medical treatment according to GOLD strategy [22] [antibiotics (fluoroquinolones), intravenous glucocorticoid (methylprednisolone), inhaled beta-agonist and anticholinergic agents via a nebulizer or a metered-dose inhaler (MDI)] and after 1 hour on oxygen, started HFNT continuously for 72 hours, as an escalation of care for their acute respiratory failure.

**Outcomes and timepoints**

Dyspnea, rated by Borg scale [25], RR, SpO₂, arterial blood gases (pH, PaO₂, pCO₂), sputum production and self-reported ease of expectoration were collected while the subject was breathing through the high-FiO₂ face mask and 1 h, 24 h, 48 h, and 72 h after initiation of HFNT. Daily entire expectorated sputum for 3 consecutive days was collected to assess the average daily sputum production. Mucus quantity was reported as ranging from 1 to 3 (1 = 1 teaspoon, 2 = 1-3 tablespoons, 3 = 1 cup). Patients rated their ease of sputum expectoration before and after treatment using a 10-cm visual analog scale (VAS, 0 = extremely easy; 10 = extremely difficult) [26] which asked ‘how easy was it to cough and expectorate sputum?’. Patients’ tolerance to the HFNT device was assessed using a VAS.

**HFNT settings**

HFNT was delivered using a dedicated high flow system (Airvo 2, Fisher & Paykel Healthcare) initially set at a gas flow of 50 L/min, temperature was set at 37°C, and FIO2 adjusted to maintain SpO₂ ≥ 92%; HFNT interface was a nasal cannula (Optiflow; Fisher & Paykel Healthcare) and the
size of interface was selected to occlude patient’s nostril of about 2/3 of their size. HFNT settings were titrated based on patients’ severity and tolerance, never falling below 35 L/min of flow rate.

**Prespecified criteria for HFNT interruption**

Severe hypoxemia (PaO\textsubscript{2}/FIO\textsubscript{2} < 100 mm Hg) or development of respiratory acidosis (pH < 7.35) requiring escalation of therapy (NIV or intubation), or increase of dyspnea, RR >30 breaths/min were considered criteria for HFNT interruption.

**Statistical analysis**

The normality of data distribution was checked graphically and by the Shapiro-Wilk test. Data are expressed as mean ± standard deviation (SD) or as median and interquartile range (IQR) when appropriate. Sphericity was assessed by Mauchly's test.

A one-way repeated measures ANOVA was conducted to determine whether there was a statistically significant difference in the variables of interest during HFNT treatment. Post-hoc analysis was performed with a Bonferroni adjustment. Epsilon (\(\varepsilon\)) was calculated according to Greenhouse and Geisser and was used to correct the one-way repeated measures.

**RESULTS**

A convenience sample of 15 consecutively admitted patients were enrolled from 82 screened (reasons for screening failure are reported in Figure 1). Table 1 summarizes the enrolled patients’ characteristics. Table 2 shows the clinical and radiological characteristics of bronchiectasis. All enrolled patients completed the pre-planned follow-up to 72 hours and there was no treatment interruption due to the pre-specified criteria. One patient had an interface displacement, between 48 and 72 hours, which was prompt solved.

Table 3 shows the assessment of study outcomes at different time points. Globally, there was a statistically significant change in RR, pCO\textsubscript{2}, pO\textsubscript{2}, Borg score, the quantity of mucus production and patients’ self-reported ease of expectoration over the course HFNT intervention (Figure 2).
Post-hoc analyses showed that pCO\textsubscript{2} decreased from baseline to 48 hours while RR and Borg scale during the first 24 hours. Mucus quantity was significantly increased at 24 hours then remained stable, while pO\textsubscript{2} was significantly increased at 72 hours in comparison to baseline values. Overall tolerance of the HFNT device evaluated through the VAS scale was 6.5. The average patients’ length of stay was 9 ± 1.5 days; 30-days readmission rate was 6.6%.

**DISCUSSION**

The main finding of our study was that HFNT might be effective to improve gas exchange, dyspnea, RR and mucus clearance in patients with AECOPD and bronchiectasis and its implementation did not show any safety concerns.

COPD and bronchiectasis are both muco-obstructive diseases [27] characterized by hyper-concentrated mucus with formation of adherent and thick mucus plaques and plugs [28], therefore the rationale for using HFNT in these patients relies on the well-known beneficial effects of high humidified and warm flow in the improvement of mucociliary transport and, in the increasing mobilization of airways secretions that lead to mucus expectoration [29].

An in vitro study [15] showed that mucociliary beating and hence mucus clearance are increased at 37 °C and 100% relative humidity, which represents the optimal condition for preserving mucosa function [30]; at these conditions, there is a reduction of mucus viscosity that helps expectoration [15]. Furthermore, Hasani et al. [16] showed that three hours per day of humidification treatment for seven days significantly increased mucociliary clearance in patients with bronchiectasis. Moreover, Rea et al. [17] showed that in a group of mixed patients with COPD and bronchiectasis an average of 1-2 hours a day of humidification treatment reduces the number of days of exacerbation and increases time on first exacerbation. Indeed, recently it has been shown the effectiveness of HFNT in the treatment of ARF due to AECOPD [18, 19, 20, 31, 32].

Our data showed that HFNT was able to significantly reduce RR of patients with ARF due to AECOPD and coexisting bronchiectasis after 24 h, and this is a very important point since
sustained high respiratory rate despite conventional oxygen therapy is indicative of a worsening prognosis in patients hospitalized for ARF and represents an early marker of potential health complications and need for ICU admission [33]. Furthermore, dyspnea had significantly improved (BORG and VAS scale).

Of note, a statistically significant reduction of pCO₂ was observed after HFNT treatment; this finding is probably due to the documented ability of HFNT of reducing dead space [34] and eventually patient’s effort [35]. We can speculate that the mechanism beyond pCO₂ improvement is also related to the concomitant increase in sputum production and patients’ self-reported ease of expectoration at 24 h compared to baseline, since the volume of secretions may be linked to the humidification provided by HFNT.

None of the patients required an escalation of treatment with NIV [36], highlighting the feasibility of using HFNT in these circumstances. Moreover, HFNT is a simple tool with an easy to wear nasal cannula that it has also the advantage of allowing patients to eat, drink and speak, and leaving them free to cough and clear their secretions, compared to oxygen facial masks or NIV interfaces. Indeed, HFNT, as opposed to NIV, does not require attention for leaks, minimizing the risk of patient-ventilator dyssynchrony [37].

Although a better comfort during HFNT is still a matter of debate [38], it could be speculated that better well-being during the time on HFNT may, in turn, lead to less need for constraints and sedation [39].

Additionally, our data confirm previous findings [40] on the benefits of HFNT for managing patients with ARF outside ICU settings.

**Strengths and limitations**

Our study has limitations, mainly related to the low sample size and the single-arm study design. Further studies with adequate sample size should test this intervention in this setting, considering stronger patient’s related outcomes.

Furthermore, due to the observational nature of the study and the single-arm design, we
cannot isolate the effects of HFNT as an adjunct to standard medical pharmacological treatment (antibiotics, bronchodilators and, corticosteroids).

In this study, the time of assessment was set at 72 hours. Although relatively short, it was enough to detect significant beneficial effects of HFNT on both gas exchange and mucous expectoration, therefore it might be enough for patients with AECOPD with bronchiectasis.

Moreover, the humidification treatment with HFNT lasted for 24 h per day for three days, unlike previous studies [16, 17, 31]; nevertheless, this prolonged treatment duration might have had a high impact on the beneficial results.

Indeed, this is the first study exploring the quantity of mucus production and patients’ ease of sputum expectoration during HFNT.

CONCLUSIONS
HFNT may be effective in improving gas exchange, dyspnea and mucus clearance in patients with AECOPD and bronchiectasis. Adequately powered and controlled studied are needed to confirm these preliminary findings.

Declaration of interest
The authors declare no conflicts of interest associated with this study.
REFERENCES

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex Male/Female, N</strong></td>
<td>8/7</td>
</tr>
<tr>
<td><strong>Age, mean (SD)</strong></td>
<td>69(4)</td>
</tr>
<tr>
<td><strong>BMI, mean (SD)</strong></td>
<td>25(5)</td>
</tr>
<tr>
<td><strong>FEV1 %, mean (SD)</strong></td>
<td>37% (7)</td>
</tr>
<tr>
<td><strong>FVC %, mean (SD)</strong></td>
<td>63% (12)</td>
</tr>
<tr>
<td><strong>FEV1/FVC %, mean (SD)</strong></td>
<td>60% (5)</td>
</tr>
<tr>
<td><strong>Smoking, N (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>7 (47%)</td>
</tr>
<tr>
<td>Ex</td>
<td>8 (53%)</td>
</tr>
<tr>
<td><strong>GOLD group, N (%)</strong></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>2 (13%)</td>
</tr>
<tr>
<td>D</td>
<td>13 (87%)</td>
</tr>
<tr>
<td><strong>GOLD grade, N (%)</strong></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>5 (33%)</td>
</tr>
<tr>
<td>4</td>
<td>10 (67%)</td>
</tr>
<tr>
<td><strong>Pack*years, median (IQR)</strong></td>
<td>45 (30-50)</td>
</tr>
<tr>
<td>&gt;3 Exacerbations/y, N (%)</td>
<td>13 (87%)</td>
</tr>
<tr>
<td><strong>Hospitalization last 12 months, N (%)</strong></td>
<td>8 (53%)</td>
</tr>
<tr>
<td><strong>MRC, median (IQR)</strong></td>
<td>4 (3-5)</td>
</tr>
<tr>
<td><strong>CAT, mean (SD)</strong></td>
<td>31 (5)</td>
</tr>
<tr>
<td><strong>Charlson Index, mean (SD)</strong></td>
<td>4 (1)</td>
</tr>
<tr>
<td><strong>LTOT, N (%)</strong></td>
<td>10 (66%)</td>
</tr>
<tr>
<td><strong>LTOT (l/min), mean (SD)</strong></td>
<td>1.6 (0.5)</td>
</tr>
</tbody>
</table>

Table 1. Patients’ characteristics.
Data are presented as mean (standard deviation) or N (%) unless otherwise stated.
BMI: Body Mass Index
GOLD: Global Initiative for Chronic Obstructive Lung Disease
MRC: medical research council
CAT: COPD assessment test
LTOT: Long Term Oxygen Therapy
GOLD group: classification based on ABCD assessment tool.
GOLD grade: classification based on airflow limitation severity.
### Lobes involved on CT, mean (SD)

<table>
<thead>
<tr>
<th>Distribution, N (%)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral</td>
<td>11 (73.3%)</td>
</tr>
<tr>
<td>Central</td>
<td>0</td>
</tr>
<tr>
<td>Diffuse</td>
<td>4 (26.7%)</td>
</tr>
<tr>
<td>Bilateral</td>
<td>14 (93.3%)</td>
</tr>
</tbody>
</table>

### Degree of dilatation, N (%)

<table>
<thead>
<tr>
<th>Distribution, N (%)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tubular</td>
<td>14 (93.3%)</td>
</tr>
<tr>
<td>Varicose</td>
<td>1 (6.6%)</td>
</tr>
<tr>
<td>Cystic</td>
<td>0</td>
</tr>
</tbody>
</table>

### BSI score, mean (SD)

<table>
<thead>
<tr>
<th>BSI score</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild (0-4)</td>
<td>0</td>
</tr>
<tr>
<td>Moderate (5-8)</td>
<td>7 (46.6%)</td>
</tr>
<tr>
<td>Severe (&gt;9)</td>
<td>8 (53.4%)</td>
</tr>
</tbody>
</table>

**Table 2. Bronchiectasis details.**

Data are presented as mean (standard deviation) or N (%) unless otherwise stated.

BSI: Bronchiectasis severity index

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>1h</th>
<th>24h</th>
<th>48h</th>
<th>72h</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>RR</td>
<td>29.6 (2.7)</td>
<td>26.2* (2.7)</td>
<td>23.1* (2.9)</td>
<td>21.3 (3.3)</td>
<td>19.6 (2.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>pH</td>
<td>7.40 (0.03)</td>
<td>7.41 (0.03)</td>
<td>7.42 (0.02)</td>
<td>7.42 (0.02)</td>
<td>7.42 (0.02)</td>
<td>0.02</td>
</tr>
<tr>
<td>pCO2</td>
<td>58.4 (13)</td>
<td>53.9* (9.1)</td>
<td>51.6* (8.2)</td>
<td>48.9* (7.3)</td>
<td>47.9 (6.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>pO2</td>
<td>61.9 (4.8)</td>
<td>65.3 (1.6)</td>
<td>67.1 (2.1)</td>
<td>67.8 (2.4)</td>
<td>68.6* (2.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BORG Score</td>
<td>6.7 (1.4)</td>
<td>4.9* (1.6)</td>
<td>4.1* (1.3)</td>
<td>3.3 (1.2)</td>
<td>3 (1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mucus Quantity</td>
<td>11 (0.6)</td>
<td>21* (0.7)</td>
<td>24 (0.7)</td>
<td>25 (0.7)</td>
<td>23 (0.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ease expectoration</td>
<td>4 (1.3)</td>
<td>5.5* (1.3)</td>
<td>6 (1.5)</td>
<td>6.5 (1.8)</td>
<td>6.8* (1.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Device Tolerance</td>
<td>-</td>
<td>6.2 (1.2)</td>
<td>6.6 (1.1)</td>
<td>6.7 (1.1)</td>
<td>6.7 (1.1)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

**Table 3.** Assessment of study outcomes at the different time-points.

Mean (SD), p value was calculated assuming sphericity or Greenhouse-Geisser correction.

*Statistically different from the previous time-point. RR: respiratory rate.

#Different from baseline
Figure Legends
Figure 1: Study design flow-chart and patients selection.
ARF: acute respiratory failure; AECOPD: acute exacerbation chronic obstructive pulmonary disease; HRCT: high resolution computed tomography; RR: respiratory rate; NIV: noninvasive ventilation; ED: emergency department; HFNT: high flow nasal cannula; ABG: arterial blood gas analysis; VAS: visual analogic scale.

Figure 2: Changes of RR, BORG scale, pO2, pCO2 at baseline and at different time points during HFNT treatment. RR: respiratory rate; HFNT: high flow nasal therapy

Figure 3: Changes of mucus production and patients’ self-reported ease of sputum expectoration at baseline and at different time points during HFNT